Pfizer Inc (PFE) stock
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 27, 2026Last filing: 10-Q on Nov 3, 2026Score 8/3044% above fair value
$28.83−0.62 (-2.11%)
Close on Nov 12, 2026Market cap $164.32BP/E 41.2Yield 5.97%
Pfizer total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Pfizer's total debt was $62.67B at Sep 27, 2026. For fiscal 2025 it was $64.80B, up 0.7% from the year before. Over ten years it grew 5.2% a year on average. The highest annual figure on record is $71.89B in fiscal 2023.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $64.80B | +0.7% |
| FY2024 | Dec 31, 2024 | $64.35B | -10.5% |
| FY2023 | Dec 31, 2023 | $71.89B | +100.6% |
| FY2022 | Dec 31, 2022 | $35.83B | -6.8% |
| FY2021 | Dec 31, 2021 | $38.44B | -3.5% |
| FY2020 | Dec 31, 2020 | $39.84B | -23.6% |
| FY2019 | Dec 31, 2019 | $52.15B | +24.9% |
| FY2018 | Dec 31, 2018 | $41.74B | -4.0% |
| FY2017 | Dec 31, 2017 | $43.49B | +3.3% |
| FY2016 | Dec 31, 2016 | $42.09B | +8.2% |
| FY2015 | Dec 31, 2015 | $38.90B | +6.0% |
| FY2014 | Dec 31, 2014 | $36.68B | +0.5% |
| FY2013 | Dec 31, 2013 | $36.49B | -2.6% |
| FY2012 | Dec 31, 2012 | $37.46B | -3.8% |
| FY2011 | Dec 31, 2011 | $38.94B | -11.5% |
| FY2010 | Dec 31, 2010 | $44.01B | -9.6% |
| FY2009 | Dec 31, 2009 | $48.66B | +181.6% |
| FY2008 | Dec 31, 2008 | $17.28B | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 27, 2026 | $62.67B | +1.6% |
| Q2 FY2026 | Jun 28, 2026 | $63.19B | +2.3% |
| Q1 FY2026 | Mar 29, 2026 | $64.46B | +3.8% |
| Q4 FY2025 | Dec 31, 2025 | $64.80B | +0.7% |
| Q3 FY2025 | Sep 28, 2025 | $61.71B | -8.8% |
| Q2 FY2025 | Jun 29, 2025 | $61.80B | -11.0% |
| Q1 FY2025 | Mar 30, 2025 | $62.11B | -10.7% |
| Q4 FY2024 | Dec 31, 2024 | $64.35B | -10.5% |
| Q3 FY2024 | Sep 29, 2024 | $67.70B | +6.5% |
| Q2 FY2024 | Jun 30, 2024 | $69.45B | +6.3% |
| Q1 FY2024 | Mar 31, 2024 | $69.54B | +93.7% |
| Q4 FY2023 | Dec 31, 2023 | $71.89B | +100.6% |
| Q3 FY2023 | Oct 1, 2023 | $63.60B | +73.4% |
| Q2 FY2023 | Jul 2, 2023 | $65.34B | +62.2% |
| Q1 FY2023 | Apr 2, 2023 | $35.89B | -1.1% |
| Q4 FY2022 | Dec 31, 2022 | $35.83B | -6.8% |
| Q3 FY2022 | Oct 2, 2022 | $36.67B | -8.0% |
| Q2 FY2022 | Jul 3, 2022 | $40.28B | +2.7% |
| Q1 FY2022 | Apr 3, 2022 | $36.30B | -8.6% |
| Q4 FY2021 | Dec 31, 2021 | $38.44B | -3.5% |
| Q3 FY2021 | Oct 3, 2021 | $39.88B | -36.8% |
| Q2 FY2021 | Jul 4, 2021 | $39.24B | -38.3% |
| Q1 FY2021 | Apr 4, 2021 | $39.70B | -24.1% |
| Q4 FY2020 | Dec 31, 2020 | $39.84B | -23.6% |
| Q3 FY2020 | Sep 27, 2020 | $63.15B | +19.9% |
| Q2 FY2020 | Jun 28, 2020 | $63.61B | +36.3% |
| Q1 FY2020 | Mar 29, 2020 | $52.29B | +15.8% |
| Q4 FY2019 | Dec 31, 2019 | $52.15B | +24.9% |
| Q3 FY2019 | Sep 29, 2019 | $52.66B | +28.3% |
| Q2 FY2019 | Jun 30, 2019 | $46.68B | +15.2% |
| Q1 FY2019 | Mar 31, 2019 | $45.14B | +10.5% |
| Q4 FY2018 | Dec 31, 2018 | $41.74B | -4.0% |
| Q3 FY2018 | Sep 30, 2018 | $41.04B | -6.6% |
| Q2 FY2018 | Jul 1, 2018 | $40.52B | -7.3% |
| Q1 FY2018 | Apr 1, 2018 | $40.84B | -7.2% |
| Q4 FY2017 | Dec 31, 2017 | $43.49B | +3.3% |
| Q3 FY2017 | Oct 1, 2017 | $43.95B | – |
| Q2 FY2017 | Jul 2, 2017 | $43.71B | – |
| Q1 FY2017 | Apr 2, 2017 | $44.01B | – |
| Q4 FY2016 | Dec 31, 2016 | $42.09B | – |
See a number that looks wrong?